Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers

Breast Cancer Research and Treatment

Volumn 148, Issue 3, 2014, Pages 675-683

  Pfeifer, Werner ^a   Sokolenko, Anna P ^a,b   Potapova, Olga N ^a   Bessonov, Alexandr A ^c   Ivantsov, Alexandr O ^a   Laptiev, Sergey A ^a,d   Zaitseva, Olga A ^a   Yatsuk, Olga S ^a   Matsko, Dmitry E ^a   Semiglazova, Tatiana Yu ^a,e   Togo, Alexandr V ^a   Imyanitov, Evgeny N ^a,b,e  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^b SAINT PETERSBURG STATE PEDIATRIC MEDICAL UNIVERSITY   (Russian Federation)

^c St Petersburg City Oncology Center   (Russian Federation)

^d PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^e NORTH WESTERN STATE MEDICAL UNIVERSITY NAMED AFTER I I MECHNIKOV   (Russian Federation)

Author keywords

BRCA1; Breast cancer; CHEK2; Germ line mutation; Neoadjuvant therapy

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; TAXANE DERIVATIVE; BRCA1 PROTEIN; CHECKPOINT KINASE 2; CHEK2 PROTEIN, HUMAN; TAXOID;

ADULT; ALLELE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RESISTANCE; CANCER STAGING; CHEK2 GENE; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; GENE; GENE MUTATION; GENOTYPE; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; RETROSPECTIVE STUDY; RUSSIAN (CITIZEN); TUMOR SUPPRESSOR GENE; ADJUVANT THERAPY; BREAST NEOPLASMS; GENETIC PREDISPOSITION; GENETICS; GERMLINE MUTATION; HETEROZYGOTE; MIDDLE AGED; PATHOLOGY;

ADULT; ANTHRACYCLINES; BRCA1 PROTEIN; BREAST NEOPLASMS; CHECKPOINT KINASE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; TAXOIDS;

EID: 84912016648     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3206-1     Document Type: Article

References (37)

1. Narod SA (2010) BRCA mutations in the management of breast cancer: the state of the art. Nat Rev Clin Oncol 7:702–707
2. Imyanitov EN, Moiseyenko VM (2011) Drug therapy for hereditary cancers. Hered Cancer Clin Pract 9:5
3. Bayraktar S, Glück S (2012) Systemic therapy options in BRCA mutation-associated breast cancer. Breast Cancer Res Treat 135:355–366
4. Maxwell KN, Domchek SM (2012) Cancer treatment according to BRCA1 and BRCA2 mutations. Nat Rev Clin Oncol 9:520–528
5. Imyanitov EN, Byrski T (2013) Systemic treatment for hereditary cancers: a 2012 update. Hered Cancer Clin Pract 11:2
6. Bardia A, Baselga J (2013) Neoadjuvant therapy as a platform for drug development and approval in breast cancer. Clin Cancer Res 19:6360–6370
7. Byrski T, Gronwald J, Huzarski T et al (2012) Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28:375–379
8. Arun B, Bayraktar S, Liu DD et al (2011) Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol 29:3739–3746
9. Yanus GA, Belyaeva AV, Ivantsov AO et al (2013) Pattern of clinically relevant mutations in consecutive series of Russian colorectal cancer patients. Med Oncol 30:686
10. Sokolenko AP, Mitiushkina NV, Buslov KG et al (2006) High frequency of BRCA1 5382insC mutation in Russian breast cancer patients. Eur J Cancer 42:1380–1384
11. Chekmariova EV, Sokolenko AP, Buslov KG et al (2006) CHEK2 1100delC mutation is frequent among Russian breast cancer patients. Breast Cancer Res Treat 100:99–102
12. Sokolenko AP, Rozanov ME, Mitiushkina NV et al (2007) Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia. Fam Cancer 6:281–286
13. Sokolenko AP, Bogdanova N, Kluzniak W et al (2014) Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations. Breast Cancer Res Treat 145:553–562
14. Iyevleva AG, Suspitsin EN, Kroeze K et al (2010) Non-founder BRCA1 mutations in Russian breast cancer patients. Cancer Lett 298:258–263
15. Suspitsin EN, Sokolenko AP, Voskresenskiy DA et al (2011) Mixed epithelial/mesenchymal metaplastic carcinoma (carcinosarcoma) of the breast in BRCA1 carrier. Breast Cancer 18:137–140
16. Lafarge S, Sylvain V, Ferrara M et al (2001) Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 20:6597–6606
17. Quinn JE, Kennedy RD, Mullan PB et al (2003) BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 63:6221–6228
18. Fourquet A, Stoppa-Lyonnet D, Kirova YM et al (2009) Familial breast cancer: clinical response to induction chemotherapy or radiotherapy related to BRCA1/2 mutations status. Am J Clin Oncol 32:127–131
19. Wong Wong Keet A, Al-Rafae M, Chappuis PO et al (2009) Long-term outcome after neo-adjuvant chemotherapy for breast cancer in BRCA1/2 carriers. Int J Cancer 125:2236–2238
20. Adams SF, Marsh EB, Elmasri W et al (2011) A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer. Gynecol Oncol 123:486–491
21. Safra T, Borgato L, Nicoletto MO et al (2011) BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin. Mol Cancer Ther 10:2000–2007
22. Kaye SB, Lubinski J, Matulonis U et al (2012) Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 30:372–379
23. Wysocki PJ, Korski K, Lamperska K et al (2008) Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations. Med Sci Monit 14:SC7–SC10
24. Kriege M, Jager A, Hooning MJ et al (2012) The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer 118:899–907
25. Tan DS, Yap TA, Hutka M et al (2013) Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer. Eur J Cancer 49:1246–1253
26. Swisher EM, Sakai W, Karlan BY et al (2008) Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 68:2581–2586
27. Davis A, Tinker AV, Friedlander M (2014) “Platinum resistant” ovarian cancer: what is it, who to treat and how to measure benefit? Gynecol Oncol 133:624–631
28. Byrski T, Dent R, Blecharz P et al (2012) Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res 14:R110
29. Byrski T, Huzarski T, Dent R et al (2014) Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 147:401–405
30. Moiseyenko VM, Protsenko SA, Brezhnev NV et al (2010) High sensitivity of BRCA1-associated tumors to cisplatin monotherapy: report of two cases. Cancer Genet Cytogenet 197:91–94
31. Silver DP, Richardson AL, Eklund AC et al (2010) Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 28:1145–1153
32. Audeh MW, Carmichael J, Penson RT et al (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376:245–251
33. Tutt A, Robson M, Garber JE et al (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376:235–244
34. Lee JM, Hays JL, Annunziata CM et al (2014) Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. J Natl Cancer Inst 106(6):dju089
35. Ledermann J, Harter P, Gourley C et al (2014) Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15:852–861
36. Moiseyenko VM, Chubenko VA, Moiseyenko FV et al (2014) Evidence for clinical efficacy of mitomycin C in heavily pretreated ovarian cancer patients carrying germ-line BRCA1 mutation. Med Oncol 31:199
37. Chrisanthar R, Knappskog S, Løkkevik E et al (2008) CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLoS One 3:e3062